UroGen begins phase 3 trial of UGN-102 to treat bladder cancer

04:24pm, Thursday, 03'rd Feb 2022 Seeking Alpha
UroGen Pharma <> began a phase 3 trial, dubbed ENVISION, of UGN-102 (mitomycin) for intravesical solution, in patients with low-grade, intermediate-risk non-muscle invasive
Wall Street analysts forecast that UroGen Pharma Ltd. (NASDAQ:URGN) will announce sales of $17.20 million for the current quarter, Zacks reports. Two analysts have issued estimates for UroGen Pharmas earnings. The lowest sales estimate is $16.50 million and the highest is $17.90 million. UroGen Pharma reported sales of $7.97 million during the same quarter last []

UroGen Pharma Ltd. (NASDAQ:URGN) Shares Purchased by Bank of America Corp DE

09:28am, Sunday, 12'th Dec 2021 Dakota Financial News
Bank of America Corp DE grew its holdings in shares of UroGen Pharma Ltd. (NASDAQ:URGN) by 169.0% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 89,635 shares of the companys stock after buying an additional 56,313 shares during the period. Bank of America []

Jason Drew Smith Sells 3,803 Shares of UroGen Pharma Ltd. (NASDAQ:URGN) Stock

02:06pm, Saturday, 04'th Dec 2021 Dakota Financial News
UroGen Pharma Ltd. (NASDAQ:URGN) General Counsel Jason Drew Smith sold 3,803 shares of the firms stock in a transaction on Tuesday, November 30th. The shares were sold at an average price of $12.03, for a total transaction of $45,750.09. The transaction was disclosed in a filing with the SEC, which is accessible through this link. []
Wall Street brokerages predict that UroGen Pharma Ltd. (NASDAQ:URGN) will post earnings of ($1.27) per share for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for UroGen Pharmas earnings, with estimates ranging from ($1.39) to ($1.08). UroGen Pharma reported earnings of ($1.38) per share during the same quarter last year, which []

UroGen Pharma Ltd. (NASDAQ:URGN) CFO Sells $31,121.61 in Stock

07:12pm, Thursday, 02'nd Dec 2021 Transcript Daily
UroGen Pharma Ltd. (NASDAQ:URGN) CFO Molly Henderson sold 2,587 shares of the companys stock in a transaction that occurred on Tuesday, November 30th. The shares were sold at an average price of $12.03, for a total value of $31,121.61. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is []
Nuveen Asset Management LLC decreased its holdings in shares of UroGen Pharma Ltd. (NASDAQ:URGN) by 5.9% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 96,600 shares of the companys stock after selling 6,054 shares during the period. Nuveen Asset Management LLC owned approximately 0.46% of UroGen Pharma []
Wall Street analysts expect that UroGen Pharma Ltd. (NASDAQ:URGN) will announce $17.20 million in sales for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for UroGen Pharmas earnings, with estimates ranging from $16.50 million to $17.90 million. UroGen Pharma reported sales of $7.97 million during the same quarter last year, which would [] The post Zacks: Analysts Anticipate UroGen Pharma Ltd. (NASDAQ:URGN) Will Announce Quarterly Sales of $17.20 Million appeared first on ETF Daily News .
Zacks Investment Research upgraded shares of UroGen Pharma (NASDAQ:URGN) from a sell rating to a hold rating in a report released on Friday, Zacks.com reports. According to Zacks, UroGen Pharma Ltd. is a clinical stage biopharmaceutical company. It focused on developing urological pathologies with a focus on uro-oncology. The companys product candidates include MitoGel and []

Urogen Pharma (URGN) Investor Presentation - Slideshow

06:58pm, Friday, 19'th Nov 2021 Seeking Alpha
UroGen Pharma (NASDAQ:URGN) released its earnings results on Monday. The company reported ($1.35) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.26) by ($0.09), MarketWatch Earnings reports. UroGen Pharma had a negative net margin of 349.05% and a negative return on equity of 127.56%. During the same quarter in the […]
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE